Publication | Open Access
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase <scp>II</scp> Study
26
Citations
36
References
2024
Year
Dupilumab monotherapy treatment for 24 weeks did not improve desensitization to peanut exposure after food challenge.
| Year | Citations | |
|---|---|---|
Page 1
Page 1